The first limitation of this study is the number of healthy subjects being smaller than the patient group, with a case-control ratio of 4:1, due to the fact that our main objective was to study BDNF in an MS population, with its dynamic changes and the treatment influence. This evidence concerns the gene BDNF and myeloid sarcoma.